I

Q1 2015
Interim Report

For further information, please contact

Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)

For further information, please contact

Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)

DATE OF PUBLICATION: 12 MAY 2015

I. Management report for the first quarter of 2015

VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE; MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED; FULL-YEAR REVENUE GUIDANCE RAISED

FINANCIAL HIGHLIGHTS

Strong EVT Execute, clear investment strategy within EVT Innovate

— Group revenues +22% to € 21.5 m (2014: € 17.6 m); EVT Execute revenues up 21% compared to the prior year period; EVT Innovate increased R&D investments by 41%
— Group EBITDA before contingent considerations at € (0.3) m significantly improved compared to the same period of the previous year (2014: € (1.3) m); positive EBITDA before contingent considerations of € 3.5 m for EVT Execute
— Very strong liquidity position at € 95.8 m (before cash received from the Sanofi transaction)
— High and stable equity ratio at 71.6%

OPERATIONAL HIGHLIGHTS

EVT Execute

Expanding project portfolio leads to significant growth in revenues

- New CNS alliance with C4X Discovery in stress-related addictive disorder programme
- Evotec and New York University Office of Therapeutic Alliances initiate multiple programmes
- Signing of various screening projects with Japanese Pharma companies
- Opening of new protein production facility in Princeton (USA)
- Initial success and extension with Padlock Therapeutics
- Evotec Hamburg receives AAALAC accreditation
- Long-term collaboration for multiple drug discovery services signed as part of Sanofi alliance (effective 01 April 2015)

EVT Innovate

Research investments and partnering strategy to drive biotech upside

- Strategic discovery and development collaboration with Second Genome (USA)
- Significant expansion of oncology portfolio planned through Sanofi alliance including four advanced, pre-clinical projects and further discovery-stage assets
- Product development alliance with Roche for EVT302 in Alzheimer's disease on track to deliver results from Phase IIb study in the first half of 2015
- Further product development alliances on track (EVT100, EVT201, EVT401)

SANOFI TRANSACTION UPDATE

Acceleration of EVT Execute and EVT Innovate through major strategic collaboration with Sanofi

- Closing of multi-component transaction between Sanofi and Evotec on 31 March 2015 (effective 01 April 2015)

GUIDANCE 2015

Revenue guidance for 2015 raised due to Sanofi alliance

- Group revenues excluding milestones, upfronts and licences now expected to increase by more than 35% (from more than 20%)
- Adjusted EBITDA positive
- R&D expenditure is expected to grow to € 15 m – € 20 m
- Liquidity is expected to be well in excess of € 100 m
- Capacity and capability building continued with up to € 10 m

1. FINANCIAL HIGHLIGHTS

Strong EVT Execute, clear investment strategy within EVT Innovate

Revenues from the EVT Execute segment amounted to € 23.1 m in the first quarter of 2015, an increase of 21% compared to the same period of the previous year (2014: € 19.2 m). Included in this amount are € 5.4 m of intersegment revenues. The EVT Innovate segment generated revenues of € 3.8 m. Gross margin at EVT Execute was 24.8% while EVT Innovate generated a gross margin of 46.2%. R&D expenses of EVT Innovate were € 4.6 m in the first quarter 2015 and increased by 41% compared to the same period of the previous year (2014: € 3.2 m). The EVT Execute segment's adjusted EBITDA before changes in contingent consideration was positive at € 3.5 m in the first three months of 2015 and significantly improved compared to the same period of the previous year (2014: € 2.3 m). The EVT Innovate segment reported an EBITDA before changes in contingent consideration of € (3.8) m. This was unchanged compared to the same period of the previous year.

Evotec's Group revenues for the first quarter of 2015 amounted to € 21.5 m, an increase of 22% compared to the same period of the previous year (2014: € 17.6 m). This increase includes a favourable currency impact. Excluding milestones, upfronts and licences, Evotec's revenues for the first quarter of 2015 amounted to € 18.5 m and increased by 14% over the same period of the previous year (2014: € 16.3 m). Excluding revenues from the acquired business of Euprotec, the increase would have been 7% compared to the same period of the previous year (2014: € 16.3 m). This growth was driven by an increase in revenues within the Company's existing drug discovery alliances and new collaborations. Milestone and upfront revenues for the first three months of 2015 included predominantly revenues from the collaboration with Second Genome.

Adjusted Group EBITDA for the first three months of 2015 amounted to € (0.3) m (first three months of 2014: € (1.3) m). Consistent with previous quarters, EBITDA was adjusted for changes in contingent consideration. As it has often been stated previously, it is important to highlight that the EBITDA of Evotec may vary significantly between quarters as a result of the timing of performance-based milestone payments and partnering events. EBITDA for the first quarter also included remaining acquisition costs associated with the Sanofi alliance.

Overall, the Company is on track to achieve a positive EBITDA (before changes in contingent consideration, if any) at the end of 2015.

Liquidity including cash, cash equivalents and investments at the end of March 2015 was strong at € 95.8 m. This liquidity position does not include the cash from the Sanofi transaction of more than € 40 m which was received in April 2015.

2. OPERATIONAL HIGHLIGHTS

Evotec manages its drug discovery activities under the business segments ***EVT Execute*** *and* ***EVT Innovate****. EVT Execute represents all partnerships in which the partner brings the underlying target or project to the collaboration. EVT Innovate comprises all partnerships derived from Evotec's internal research. Further information on the segments EVT Execute and EVT Innovate can be found in the "Corporate objectives and strategy" section on page 31 of Evotec's Annual Report 2014.*

EVT Execute
Expanding project portfolio leads to significant growth in revenues

New CNS alliance with C4X Discovery in stress-related addictive disorder programme
In January 2015, Evotec announced a research collaboration with C4X

Discovery Holdings plc ("C4XD") to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology. In this collaboration, Evotec applies its drug discovery platform and its expertise in computational chemistry, medicinal chemistry and pharmacology to further develop several series of Orexin-1 selective inhibitors.

Evotec and New York University Office of Therapeutic Alliances initiate multiple programmes
In the first quarter of 2015, Evotec and The Office of Therapeutic Alliances at New York University ("NYU") initiated multiple programmes with the goal of accelerating the next generation of innovative therapeutics to come out of NYU's academic labs. The collaboration leverages synergistic strengths from both organisations to advance programmes for further investment by biopharma, venture capital, and/or not-for-profit foundations.

Signing of various screening projects with Japanese Pharma companies
In March 2015, Evotec initiated a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. In addition, Evotec's activity in the Asian market gained momentum, resulting in various new drug discovery alliances with large Japanese pharmaceutical companies, which provide a solid foundation for future growth in this area.

Opening of new protein production facility in Princeton (USA)
Evotec's new facility in Princeton, NJ, USA, became operational in the first quarter of 2015. Having been converted into a functioning drug discovery facility, it will support protein production and other discovery services for East Coast-based Pharma clients. The new facility is modular in approach, meaning that it is scalable to accommodate future business growth. This addition complements the expansion of such services at the Abingdon facility and meets an increasing need to deliver services to major US partners.

Initial success and extension with Padlock Therapeutics
In January 2015, Evotec and Padlock Therapeutics, Inc. announced the successful completion of the initial goal in a programme focused on developing inhibitors of protein-arginine deiminases (PADs) enzymes with an important role in the generation of autoantigens, inflammation and immune complex formation in autoimmune diseases, and have further extended the collaboration that was first signed in January 2014. The collaboration now extends through March 2017.

Evotec Hamburg receives AAALAC accreditation
In the first quarter of 2015, Evotec's *in vivo* pharmacology facility in Hamburg, Germany, received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care ("AAALAC") International. AALAC International is a private, non-profit organisation that promotes the humane treatment of animals in science through voluntary accreditation and assessment programmes. Participation in this accreditation programme includes a very thorough examination and assessment of facilities and processes.

Long-term collaboration for multiple drug discovery services signed as part of Sanofi alliance (effective 01 April 2015)
Evotec will provide a broad range of long-term drug discovery services to Sanofi. This agreement is centred on the core small-molecule discovery platforms in Toulouse for the period of the contract over the next five years.

EVT Innovate
Research investments and partnering strategy to drive biotech upside

Strategic discovery and development collaboration with Second Genome (USA)
In March 2015, Evotec and Second Genome, Inc. announced a small molecule-based discovery and development collaboration aimed at the treatment of microbiome-mediated diseases. The agreement between Evotec and Second Genome triggered an undisclosed upfront payment. Furthermore, Evotec is eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments relating to the commercialisation of any product.

Significant expansion of oncology portfolio planned through Sanofi alliance including four advanced, pre-clinical projects and further discovery-stage assets
Evotec has been active in oncology for several years constantly building its portfolio drug discovery alliances and drug product opportunities. Through the Sanofi alliance, Evotec intends to significantly expand its portfolio of proprietary oncology projects by more than 15 projects. Four of these projects include compounds in pre-clinical development covering mechanisms such as targeting of growth factor receptors, cancer metabolism and cancer immunity.

Product development alliance with Roche for EVT302 in Alzheimer's disease on track to deliver results from Phase IIb study in the first half of 2015
The patient recruitment for the Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4602522 (RG1577/EVT302) in patients with moderate severity Alzheimer's disease was completed in the first quarter of 2014 (544 patients). Roche and its subsidiary Chugai (Japan) have also initiated and completed several Phase I safety trials during 2014. This clinical trial is one of very few late-stage trials in this AD patient population. Results from the Phase IIb study are expected in the first half of 2015.

Further product development alliances on track (EVT100, EVT201, EVT401)
In 2014, Janssen decided to focus on another compound from the EVT100 series in CNS. This alliance with Janssen on the EVT100 series is ongoing.

In 2014, JingXin Pharmaceutical Co., Ltd. (China) initiated a Phase II study alongside the Phase I multiple dose study with EVT201. Patient recruitment and drug preparation for the Phase II study are ongoing.

In the first half of 2014, CONBA (China) completed *in vivo* efficacy studies for EVT401 which demonstrated that EVT401 is effective against experimental arthritis in non-human primates. Development of a clinical formulation is ongoing for use in clinical trials.

3. SANOFI TRANSACTION UPDATE

Acceleration of EVT Execute and EVT Innovate through major strategic collaboration with Sanofi

Closing of multi-component transaction between Sanofi and Evotec on 31 March 2015 (effective 01 April 2015)

On 31 March 2015, Evotec closed the five-year, major multi-component strategic alliance with Sanofi. The major cornerstones of the alliance are: Acquisition of Sanofi's research site in Toulouse, France, including more than 200 highly experienced employees; the planned licensing of a portfolio of oncology-related projects, including four advanced, pre-clinical projects and further discovery-stage assets; a major outsourcing alliance supplying various discovery services to Sanofi over a five-year period; management of Sanofi's global screening library; and a ground-breaking industry initiative whereby Evotec will combine its own and Sanofi's compound libraries and make them available for screening projects to Evotec's partners. The collaboration results in a minimum guaranteed commitment from Sanofi to Evotec of € 250 m over the next five years, including more than € 40 m upfront cash payment.

4. GUIDANCE 2015

As a result of the Sanofi alliance, Evotec raises its revenue guidance for 2015 from the guidance which was published on 24 March 2015. Group revenues excluding milestones, upfronts and licences are now expected to increase by more than 35% (previously: more than 20%). This increase is due to the refinement of the accounting treatment of the Sanofi transaction and has no impact on the profitability. With respect to further information on the guidance, please refer to the "Financial outlook" section on page 13 of this quarterly report.

A. OPERATIONS

Changes in Group structure, corporate strategy and objectives, product offering and business activities

During the first quarter of 2015, no changes occurred with regards to Evotec's **Group structure**. However, Evotec's Group structure in the first quarter of 2015 is different from the Group structure in the first quarter of 2014 due to the acquisitions of Bionamics GmbH (effective 01 April 2014) and Euprotec Ltd (effective 27 May 2014).

The Company continues to be managed in line with the **corporate objectives and strategy** described in Evotec's Annual Report 2014 on pages 31 and 32. Evotec operates through its two business segments EVT Execute and EVT Innovate. These segments effectively comprise different project types operating from a common platform and both play an important role in successfully delivering on the Company's strategy. Evotec's "Action Plan 2016 – Innovation Efficiency" is on track and updates on EVT Execute and EVT Innovate are described in detail on pages 3 to 6 of this quarterly report. At the end of 2014, specific objectives for 2015 were defined for the segments EVT Execute and EVT Innovate which are described in

Evotec's Annual Report 2014 on page 69.

B. REPORT ON THE FINANCIAL SITUATION AND RESULTS

COMPARISON OF THE FIRST QUARTER 2015 FINANCIAL RESULTS WITH FORECAST

Evotec does not provide forecasts on a quarterly basis.

1. RESULTS

Revenues

Evotec's **revenues** for the first quarter of 2015 grew to € 21.5 m, an increase of 22% compared to the same period of the previous year (2014: € 17.6 m). This increase includes a favourable currency impact. Excluding milestones, upfronts and licences, Evotec's revenues for the first quarter of 2015 were € 18.5 m and would have increased by 14% over the same period of the previous year (2014: € 16.3 m). Excluding revenues from the acquired business of Euprotec, the increase would have been 7% compared to the same period of the previous year (2014: € 16.3 m). This growth was driven by an increase in revenues within the Company's existing drug discovery alliances and new collaborations. Milestone and upfront revenues for the first three months of 2015 included predominantly revenues from the collaboration with Second Genome.

Geographically 66% of Evotec's revenues were generated with customers in the USA, 33% with customers in Europe and 1% with customers in Japan and the rest of the world. This compares to 61%, 37% and 2%, respectively, in the same period of the previous year.

Operating cost structure

Costs of revenue for the first quarter of 2015 amounted to € 14.9 m (2014: € 13.0 m), yielding a **gross margin** of 30.7% (2014: 26.2%). This reflected the benefits of continuing optimisation and improvement initiatives as well as a higher milestone contribution to Group revenues than in the previous year.
As has often been stated, gross margins in the future may be volatile and the receipt of potential milestone or out-licensing payments may affect Evotec's financial results.

R&D expenses for the first quarter of 2015 increased as planned by 29% to € 3.8 m (2014: € 3.0 m). The increase is primarily due to increased investments in Cure *X* and Target *X* initiatives.

SG&A expenses for the first quarter of 2015 increased by 17% to € 5.1 m (2014: € 4.4 m). This increase is mainly due to transaction costs relating to the strategic collaboration with Sanofi and adverse foreign exchange rate movements.

In the first three months of 2015, **amortisation** decreased slightly to € 0.6 m from € 0.8 m in the same period of the previous year.

Other operating income and expenses, net in the first three months of 2015 amounted to € (0.4) m (2014: € 0.0 m).

Financial results

EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. EBITDA excludes impairments on goodwill, intangible and tangible assets as well as the total non-operating result. Adjusted Group EBITDA was effectively break even for the first three months of 2015 and amounted to € (0.3) m (first three months of 2014: € (1.3) m). EBITDA was adjusted for changes in contingent consideration. Evotec's **operating loss** for the first quarter of 2015 decreased to € 3.3 m (2014: € 3.5 m).

The **net result** amounted to € (1.1) m (2014: € (4.0) m), mainly due to favourable foreign exchange rate effects.

Earnings per share for the first quarter of 2015 were € (0.01) (2014: € (0.03)).

2. OPERATING SEGMENTS EVT EXECUTE AND EVT INNOVATE

Segment reporting

The Company operates, manages and reports its business under two segments, EVT Execute and EVT Innovate. A more detailed description of the segments as well as a table showing the segment information can be found on pages 20 to 22 of this quarterly report.

Revenues from the EVT Execute segment amounted to € 23.1 m in the first quarter of 2015, an increase of 21% compared to the previous year (first three months of 2014: € 19.2 m). This increase is primarily attributable to growth of the base business, supported by a positive development of the anti-infectives business and foreign exchange rate effects. Included in this amount are € 5.4 m of intersegment revenues (first three months of 2014: € 4.0 m). The EVT Innovate segment generated revenues in the amount of € 3.8 m consisting entirely of third party revenues (first three months of 2014: € 2.5 m).

The EVT Execute segment recorded costs of revenue of € 17.4 m in the first three months of 2015 (first three months of 2014: € 14.7 m), resulting in a gross margin of 24.8% compared to 23.5% in the prior year period. The EVT Innovate segment reported costs of revenue of € 2.1 m (first three months of 2014: € 1.8 m), resulting in a gross margin of 46.2% compared to 27.2% in the prior year period. This significant increase was primarily due to the licence upfront and milestone payment from the collaboration with Second Genome.

R&D expenses for the EVT Innovate segment increased from € 3.2 m in the first three months of 2014 to € 4.6 m in the first three months of 2015 due to the increased investment in Cure *X* and Target *X* initiatives.

In the first three months of 2015, SG&A expenses for the EVT Execute segment amounted to € 3.8 m compared to € 3.3 m in the prior year period and SG&A expenses for the EVT Innovate segment remained relatively stable at € 1.3 m compared to € 1.1 m in the prior year period. The increases of SG&A expenses within both business segments are mainly attributable to transaction-related costs regarding the strategic alliance with Sanofi.

In the first three months of 2015, the adjusted EBITDA (before changes in contingent consideration) of the EVT Execute segment was positive at € 3.5 m. It improved compared to the same period of the previous year (first three months of 2014: € 2.3 m). The EVT Innovate segment reported an EBITDA before changes in contingent consideration of € (3.8) m, which was unchanged compared to the same period of the previous year.

3. FINANCING AND FINANCIAL POSITION

Cash flow and liquidity

Cash provided by operating activities for the first three months of 2015 amounted to € 7.4 m (first three months of 2014: cash used in operating activities of € 5.1 m). This mainly reflects the receipt of milestone payments in the first quarter of 2015 from the collaboration with Bayer, which were recognised as revenues in the fourth quarter of 2014.

The line item "Adjustments to reconcile net loss to net cash used in operating activities" in the condensed cash flow statement amounted to € 2.7 m and mainly consisted of depreciation of property, plant and equipment (€ 1.5 m), amortisation (€ 0.6 m) and compensation expenses (€ 0.4 m).

Cash used in investing activities for the first three months of 2015 amounted to € 7.0 m compared to cash used in investing activities of € 1.0 m in the same period of the previous year. Purchases of current investments (€ 24.9 m) exceeded the proceeds from the sale of current investments (€ 20.4 m). Capital expenditures increased to € 2.5 m from € 0.9 m in the same period of the previous year. The investments in the first quarter of 2015 included the fit-out of the new protein production facility in Princeton (USA) and the expansion of the laboratory area in Abingdon (UK).

Cash provided by financing activities for the first three months of 2015 was € 0.6 m (2014: cash used in financing activities of € 0.2 m) and mainly resulted from an increase in long-term debt to finance selected EVT Innovate projects.

Liquidity, which includes cash and cash equivalents (€ 49.3 m) and investments (€ 46.5 m) amounted to € 95.8 m at the end of March 2015 (31 December 2014: € 88.8 m). This increase in liquidity is mainly attributable to the cash inflow as a result of the receipt of milestone payments in the context of the Bayer collaboration.

4. ASSETS, LIABILITIES AND STOCKHOLDERS' EQUITY

The material changes in assets and liabilities during the first three months of 2015 are mentioned below. More details are described in the notes to the unaudited consolidated interim financial statements on pages 22 to 23 of this quarterly report.

Assets

Trade accounts receivables decreased to € 13.8 m (31 December 2014: € 25.3 m) in the first quarter of 2015. This decrease is mainly due to the receipt of milestone payments in the first quarter 2015 which were recorded as revenues at the end of 2014.

Due to increased foreign exchange rates, goodwill increased to € 47.2 m in the first quarter of 2015 (31 December 2014: € 44.8 m).

Changes in **liquidity** are explained above under "Financing and financial position".

The Company was not involved in any off-balance-sheet financing transactions.

Liabilities
Trade accounts payables decreased to € 6.8 m (31 December 2014: € 9.5 m) mainly due to payments related to the Sanofi transaction and to the alliance with Haplogen. Furthermore, this increase results from a significant volume of compound purchases which had been invoiced at 31 December 2014.

The increase in current provisions to € 4.6 m (31 December 2014: € 3.7 m) in the first quarter of 2015 mainly reflects the increase in the short-term earn-out provision related to the Euprotec acquisition (€ 0.2 m) as well as higher provisions for personnel expenses due to a portion of the bonus 2014 being only paid in April 2015 (€ 0.4 m).

Non-current provisions increased to € 18.9 m in the first quarter of 2015 (31 December 2014: € 18.0 m) mainly due to fair value adjustments relating to earn-outs in the context of the acquisitions of DeveloGen, Euprotec and Bionamics (€ 0.9 m).

Stockholders' equity
As of 31 March 2015, Evotec's **capital structure** remained unchanged compared to the end of 2014. Due to the exercise of stock options, there were 131,734,876 shares issued and outstanding with a nominal value of € 1.00 per share as of 31 March 2015. Included in this amount as of 31 March 2015 were 269,065 treasury shares that were generated in the course of the acquisition of Renovis, Inc. by Evotec AG.

Evotec's equity ratio as of 31 March 2015 continued to be high and stable at 71.6% (31 December 2014: 70.5%).

5. HUMAN RESOURCES

Employees
At the end of March 2015, 727 people were employed within the Evotec Group (31 December 2014: 717 employees). The headcount was increased in the first quarter of 2015 to support the growth of the EVT Execute and EVT Innovate business.
Effective after period-end on 01 April 2015, Evotec acquired Sanofi's scientific operations in Toulouse, France – including 208 highly experienced employees – and is in the process of integrating them into its global drug discovery platform.

Stock-based compensation
In the first three months of 2015, no stock options were granted to Evotec employees and a total of 27,250 options were exercised: 3,250 options were serviced out of treasury shares, 24,000 options were serviced from contingent capital. As of 31 March 2015, the total number of options available for future exercise amounted to 2,966,696 (approximately 2.3% of shares in issue).

In 2012, the Company implemented a share performance plan. During the first quarter of 2015, no share performance awards were granted to members of the Management Board and other key employees and no share performance awards were exercised. As of 31 March 2015, the total number of share performance awards available for future exercise amounted to 3,090,348 (approximately 2.3% of shares in issue).

Options and share performance awards have been accounted for under IFRS 2 using the fair value at the measurement date. In the first three months of 2015, no options and share performance awards held by employees of the Company continued to be valid after termination of the relating employment.

Shareholdings of the Boards of Evotec AG
Number of shares

	01 Jan 15	Additions	Sales	31 March 15
Management Board				
Dr Werner Lanthaler	526,494	-	-	526,494
Colin Bond	-	-	-	-
Dr Cord Dohrmann	41,387	4,831	-	46,218
Dr Mario Polywka	60,000	-	-	60,000
Supervisory Board				
Prof. Dr Wolfgang Plischke	-	-	-	-
Dr Walter Wenninger	38,538	-	-	38,538
Dr Claus Braestrup	-	-	-	-
Prof. Dr Paul Herrling	-	-	-	-
Bernd Hirsch	-	-	-	-
Prof. Dr Iris Löw-Friedrich	-	-	-	-

Number of stock options

	01 Jan 15	Additions	Exercise	31 March 15
Management Board				
Dr Werner Lanthaler	940,000	-	-	940,000
Colin Bond	290,000	-	-	290,000
Dr Cord Dohrmann	340,000	-	-	340,000
Dr Mario Polywka	398,792	-	-	398,792
Supervisory Board				
Prof. Dr Wolfgang Plischke	-	-	-	-
Dr Walter Wenninger	-	-	-	-
Dr Claus Braestrup	-	-	-	-
Prof. Dr Paul Herrling	-	-	-	-
Bernd Hirsch	-	-	-	-
Prof. Dr Iris Löw-Friedrich	-	-	-	-

Number of Share Performance Awards

	01 Jan 15	Additions	Exercise	31 March 15
Management Board				
Dr Werner Lanthaler	722,748	-	-	722,748
Colin Bond	284,859	-	-	146,204
Dr Cord Dohrmann	303,830	-	-	303,830
Dr Mario Polywka	305,043	-	-	150,631
Supervisory Board				
Prof. Dr Wolfgang Plischke	-	-	-	-
Dr Walter Wenninger	-	-	-	-
Dr Claus Braestrup	-	-	-	-
Prof. Dr Paul Herrling	-	-	-	-
Bernd Hirsch	-	-	-	-
Prof. Dr Iris Löw-Friedrich	-	-	-	-

Pursuant to § 15a of the German Securities Trading Act (Wertpapierhandelsgesetz), the above tables list the number of Company shares held and rights for such shares granted to each board member as of 31 March 2015 separately for each member of our Management and Supervisory Boards.

C. RISKS AND OPPORTUNITIES REPORT

The risks and opportunities described in Evotec's Annual Report 2014 on pages 60 to 67 remain unchanged. At present, no risks have been identified that either individually or in combination could endanger the continued existence of Evotec AG.

D. IMPORTANT EVENTS AFTER THE END OF THE FIRST QUARTER OF 2015

Closed on 31 March 2015 and effective 01 April 2015, Evotec entered into a major multi-component strategic alliance over the next five years with Sanofi. This multi-faceted collaboration encompasses a long-term discovery service collaboration with Sanofi, a major planned pipeline-building initiative with the focus on oncology, the acquisition of Sanofi's scientific operations and related employees at the Toulouse site, the creation of Evotec's European compound management centre and Sanofi's and Evotec's offering of their joint small molecule libraries to biotech and other Pharma players for hit discovery. Furthermore, this alliance establishes the French academic bridge in order to further energise and accelerate the translation of excellent science from academic institutions to Pharma.

E. TRANSACTIONS WITH RELATED PARTIES

Except for the transactions described in Evotec's Annual Report 2014 on page 114, no other material transactions with related parties were entered into in the first quarter of 2015.

F. BUSINESS ENVIRONMENT

Global economy and outlook

In the first quarter of 2015, several factors affected global economic growth, such as high volatility in exchange rates, the rapid decline in oil prices and the new quantitative easing programme of the European Central Bank as well as ongoing political conflicts in the Middle East and in Ukraine. According to forecasts by the World Bank in January 2015, overall global growth is expected to increase to 3.0% in 2015 compared to 2.6% in 2014. In the USA, economic growth is expected to accelerate to 3.2% in 2015 compared to 2.4% in 2014. The forecast for Eurozone growth in 2015 is low at 1.1% (0.8% in 2014). For Asia, forecasts anticipate continued robust growth. These expectations, relating to the overall situation, are subject to considerable uncertainties. One key factor will be the timing and extent to which monetary policy accommodation is withdrawn by central banks.

Healthcare environment and outlook
The significant rise in costs to take a drug to market has led to a number of key trends, including an increase in outsourcing and major Pharma companies concentrating on fewer core disease areas. In the past decade, the pharmaceutical industry has suffered from decreasing efficiency in new product introductions. According to a report by Visiongain (2015), as a consequence, the pharmaceutical industry is increasingly shifting its focus away from the traditional blockbuster business model which relied on vertical integration to a model which recognises the importance of outsourcing certain functions and looking to external opportunities from innovative biotech companies that offer services in drug research to deliver high-quality leads and development candidates.

G. FINANCIAL OUTLOOK

Revenue guidance for 2015 adjusted, other financial targets for 2015 confirmed
With the exception of the revenue guidance, all of the financial targets published on 24 March 2015 remain unchanged. The adjusted revenue target for 2015 is described below. *Note*: The financial guidance announced on 24 March 2015 differs from the guidance provided in the Annual Report 2014 as a result of the financial impact of the Sanofi transaction.

In 2015, total Group revenues excluding milestones, upfronts and licences are now expected to increase more than 35% (up from more than 20%) This increase is due to the refinement of the accounting treatment of the Sanofi transaction and has no impact on the profitability.

Evotec's Group EBITDA before changes in contingent considerations is expected to be positive. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation of intangibles. EBITDA excludes impairments on intangible, tangible assets and goodwill as well as the total non-operating result.

Evotec expects research and development (R&D) expenses to grow to € 15 m – € 20 m in 2015.

In 2015, Evotec will continue to invest in its technology platforms and capacities in order to drive its long-term growth strategy. It is therefore planned that up to € 10 m will be invested in further capacity increases and the upgrade of Evotec's technological capabilities.

Liquidity is expected to be well in excess of € 100 m at 31 December 2015. This forecast excludes any potential cash outflow from M&A or similar transactions.

The Company's mid-term financial plan does not envisage the need for any additional external financing for Evotec's operating business. However, all strategically desirable moves such as potential company or product acquisitions will need to be considered on a case by case basis.

The statements on **business direction and strategy**, **expected research and development**, **business opportunities** and **dividends** continue to be valid as published in Evotec's Annual Report 2014 on pages 68 to 70.

H. SHARE PRICE PERFORMANCE AND FINANCIAL CALENDAR

Performance of Evotec shares over the past twelve months



The DAX index closed the first quarter of 2015 up 23% at 11,966 points. This market momentum is mainly attributable to the weakening of the Euro as well as the quantitative easing programme of the European Central Bank, which was initiated in March 2015. Evotec's share price ended the first quarter of 2015 at € 3.76 and remained largely unchanged compared to its opening price for 2015 (€ 3.77). This compares to an increase of 17% for the German technology stock index TecDAX.

Financial Calendar 2015

Q1 2015 Interim Report:	12 May 2015
Annual General Meeting 2015:	09 June 2015
Half-year 2015 Interim Report:	12 August 2015
Nine-month 2015 Interim Report:	10 November 2015

II. Consolidated interim financial statements

Evotec AG and subsidiaries -

Consolidated interim income statement for the period from 1 January to 31 March 2015

in T€ except share and per share data	*Three months ended 31 March 2015*	*Three months ended 31 March 2014*
Revenues	21,542	17,611
Costs of revenue	(14,919)	(12,998)
Gross profit	**6,623**	**4,613**
Operating income and (expenses)		
Research and development expenses	(3,834)	(2,972)
Selling, general and administrative expenses	(5,118)	(4,356)
Amortisation of intangible assets	(587)	(760)
Other operating income	1,258	452
Other operating expenses	(1,642)	(459)
Total operating expenses	**(9,923)**	**(8,095)**
Operating loss	**(3,300)**	**(3,482)**
Other non-operating income (expense)		
Interest income	178	125
Interest expense	(406)	(449)
Profit share from associated companies	(7)	-
Foreign currency exchange gain (loss), net	2,031	(273)
Other non-operating income	136	25
Total non-operating income (expense)	**1,932**	**(572)**
Loss before taxes	**(1,368)**	**(4,054)**
Current tax income	213	-
Deferred tax income	83	48
Total taxes	**296**	**48**
Net loss	**(1,072)**	**(4,006)**
Weighted average shares outstanding	**131,450,783**	**131,162,211**
Net loss per share (basic/diluted)	**(0.01)**	**(0.03)**

Evotec AG and subsidiaries -
Consolidated statement of comprehensive income for the period from 1 January to 31 March 2015

in T€	*Footnote reference*	*Year ended 31 March 2015*	*Year ended 31 March 2014*
Net loss		**(1,072)**	**(4,006)**
Accumulated other comprehensive income			
Items which are not re-classified to the income statement			
Remeasurement of defined benefit obligation		-	-
Taxes		-	-
Items which have to be re-classified to the income statement at a later date			
Foreign currency translation		5,277	535
Revaluation and disposal of available-for-sale securities		302	13
Taxes		-	-
Other comprehensive income		**5,579**	**548**
Total comprehensive income		**4,507**	**(3,458)**

Evotec AG and subsidiaries -
Consolidated interim statement of financial position as of 31 March 2015

in T€ except share data	*Footnote reference*	*As of 31 March 2015*	*As of 31 Dec. 2014*
ASSETS			
Current assets:			
Cash and cash equivalents		49,284	48,710
Investments		46,490	40,112
Trade accounts receivables	6	13,804	25,259
Inventories		3,772	3,111
Current tax receivables		1,535	887
Other current financial assets	7	1,908	1,094
Prepaid expenses and other current assets	8	7,049	6,127
Total current assets		**123,842**	**125,300**
Non-current assets:			
Associated companies and long-term investments		5	13
Property, plant and equipment		25,816	24,045
Intangible assets, excluding goodwill		30,968	30,210
Goodwill		47,192	44,815
Other non-current financial assets		78	78
Other non-current assets		96	139
Total non-current assets		**104,155**	**99,300**
Total assets		**227,997**	**224,600**
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Current loan liabilities		13,512	13,363
Trade accounts payables	9	6,822	9,450
Advanced payments received		284	542
Provisions	10	4,618	3,694
Deferred revenues		2,439	2,806
Current income tax payables		850	1,046
Other current financial liabilities		998	1,384
Other current liabilities		1,294	783
Total current liabilities		**30,817**	**33,068**
Non-current liabilities:			
Non-current loan liabilities	11	8,719	8,186
Deferred tax liabilities		1,643	1,583
Provisions	12	18,900	17,957
Deferred revenues		3,550	4,344
Other non-current financial liabilities		1,041	1,079
Total non-current liabilities		**33,853**	**33,149**
Stockholders' equity:			
Share capital		131,735	131,711
Additional paid-in capital		689,082	688,669
Accumulated other comprehensive income		(17,590)	(23,169)
Accumulated deficit		(639,900)	(638,828)
Total stockholders' equity		**163,327**	**158,383**
Total liabilities and stockholders' equity		**227,997**	**224,600**

Evotec AG and subsidiaries -
Condensed consolidated interim statement of cash flows for the three months ended 31 March 2015

in T€	*Three months ended 31 March 2015*	*Three months ended 31 March 2014*
Cash flows from operating activities:		
Net loss	(1,072)	(4,006)
Adjustment to reconcile net loss to net cash provided by (used in) operating activities	2,672	2,820
Change in assets and liabilities	5,788	(3,944)
Net cash provided by (used in) operating activities	**7,388**	**(5,130)**
Cash flows from investing activities:		
Purchase of current investments	(24,940)	(4,934)
Purchase of property, plant and equipment	(2,487)	(867)
Proceeds from sale of current investments	20,418	4,762
Net cash used in investing activities	**(7,009)**	**(1,039)**
Cash flows from financing activities:		
Proceeds from option exercise	49	163
Proceeds from issuance of loans	549	978
Payment of subsequent earn-outs	-	(1,313)
Repayment of loans	(45)	(46)
Net cash provided by (used in) financing activities	**553**	**(218)**
Net increase (decrease) in cash and cash equivalents	**932**	**(6,387)**
Exchange rate difference	(358)	381
Cash and cash equivalents at beginning of year	48,710	45,644
Cash and cash equivalents at end of the period	**49,284**	**39,638**

Evotec AG and subsidiaries -
Consolidated interim statement of changes in stockholders' equity
for the three months ended 31 March 2015

	Share capital			Accumulated other comprehensive income			
in T€ except share data	Shares	Amount	Additional paid-in capital	Foreign currency translation	Revaluation reserve	Accumulated deficit	Total stockholders' equity
Balance at 01 January 2014	**131,460,193**	**131,460**	**686,767**	**(34,376)**	**6,966**	**(631,850)**	**158,967**
Exercised stock options	80,630	81	82	-	-	-	163
Stock option plan	-	-	291	-	-	-	291
Total comprehensive income (loss)				**535**	**13**	**(4,006)**	**(3,458)**
Balance at 31 March 2014	**131,540,823**	**131,541**	**687,140**	**(33,841)**	**6,979**	**(635,856)**	**155,963**
Balance at 01 January 2015	**131,710,876**	**131,711**	**688,669**	**(30,043)**	**6,874**	**(638,828)**	**158,383**
Exercised stock options	24,000	24	25	-	-	-	49
Stock option plan	-	-	388	-	-	-	388
Total comprehensive income (loss)				**5,277**	**302**	**(1,072)**	**4,507**
Balance at 31 March 2015	**131,734,876**	**131,735**	**689,082**	**(24,766)**	**7,176**	**(639,900)**	**163,327**

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated interim financial statements of Evotec have been prepared in accordance with International Financial Reporting Standards (IFRS) and their interpretations as issued by the International Accounting Standards Board (IASB) and as adopted by the European Union (EU) in conjunction with IAS 34. The consolidated interim financial statements have been prepared on cost basis, except for derivative financial instruments as well as available-for-sale financial instruments, which are measured at fair value. The accounting policies used to prepare interim information are the same as those used to prepare the audited consolidated financial statements for the year ended 31 December 2014. Income tax income and expense is recognised in interim periods based on the best estimate of the weighted average annual income tax rate expected for the full financial year.

The consolidated interim financial statements do not include all of the information and footnotes required under IFRS for complete financial statements according to IAS 1. As a result, these interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended 31 December 2014.
In the opinion of the management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included.

2. BASIS OF CONSOLIDATION

In 2014, Evotec acquired all of the shares in Bionamics GmbH ("Bionamics") effective 01 April 2014 and acquired all of the shares in Euprotec Ltd ("Euprotec") effective 27 May 2014. Both entities have been fully consolidated since the respective effective dates.
Due to these acquisitions, the condensed consolidated interim financial statements for the first three months of 2014 and 2015 are not fully comparable.

3. BASIS OF ESTIMATION

In the consolidated interim financial statements for the three months ended 31 March 2015, the Company has used the same estimation processes as those used to prepare the audited consolidated financial statements for the year ended 31 December 2014.

4. SEGMENT INFORMATION

Pursuant to IFRS 8, reporting on the financial performance of the segments has to be prepared in accordance with the management approach. The internal organisation as well as the reporting to the Management Board as chief operating decision maker were changed as of 01 January 2014 so that two different segments are reported. The allocation of resources as well as the internal evaluation of Evotec's performance by management are done according to those segments. The evaluation of each operating segment by the management is

performed on the basis of revenues and EBITDA before changes in contingent consideration. EBITDA is earnings before interest, tax, depreciation and amortisation. Amortisation includes the amortisation itself as well as the impairment charges to goodwill, intangible assets and fixed assets. EBITDA is calculated without non-operating income and expense. For the EVT Innovate segment, R&D expenses are another key performance indicator. Expenses and income below operating result are not part of the segment results.
EVT Execute and EVT Innovate were identified by the Management Board as operating segments. The responsibility for EVT Execute was allocated to the COO, Dr Mario Polywka, while the responsibility for EVT Innovate was allocated to the CSO, Dr Cord Dohrmann. The organisation of the whole Evotec Group was structured accordingly.

The main activities in each of the segments are as follows:
• EVT Execute: Evotec offers stand-alone or integrated drug discovery solutions for collaborators' targets and programmes. In EVT Execute, these services are provided on a typical fee-for-service basis or through a variety of commercial structures including research fees, milestones and/or royalties. Projects are selected to match Evotec's expertise and technology.
• EVT Innovate: The segment EVT Innovate focuses on developing its own internal assets including early-stage discovery programmes as well as more advanced drug candidates, which are subsequently positioned for partnering with Pharma clients, usually at pre-clinical stages. Evotec's internal programmes focus on first-in-class and best-in-class projects based on innovative biology. These so called "Cure *X*" or "Target *X*" initiatives largely follow indication areas that are firmly established at Evotec: CNS/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Ensuing partnerships usually involve upfront and research payments as well as milestones and product royalties.

The segments' key performance indicators are used monthly by the Management Board to evaluate the resource allocation as well as Evotec's performance. Intersegment revenues are valued with a price comparable to other third-party revenues.

The segment information for the first three months of 2015 is as follows:

in T€	*EVT Execute*	*EVT Innovate*	*Intersegment eliminations*	*Evotec Group*
Revenues	23,127	3,835	(5,420)	21,542
Costs of revenue	(17,403)	(2,064)	4,548	(14,919)
Gross profit	**5,724**	**1,771**	**(872)**	**6,623**
Operating income and (expenses)				
Research and development expenses	(135)	(4,571)	872	(3,834)
Selling, general and administrative expenses	(3,849)	(1,269)	-	(5,118)
Amortisation of intangible assets	(493)	(94)	-	(587)
Other operating income	1,032	226	-	1,258
Other operating expenses	(1,573)	(69)	-	(1,642)
Total operating expenses	**(5,018)**	**(5,777)**	**872**	**(9,923)**
Operating income (loss)	**706**	**(4,006)**	**-**	**(3,300)**
EBITDA adjusted	**3,522**	**(3,849)**	**-**	**(327)**

The segment information for the first three months of 2014 is as follows:

in T€	EVT Execute	EVT Innovate	Intersegment eliminations	Evotec Group
Revenues	19,175	2,469	(4,033)	17,611
Costs of revenue	(14,664)	(1,798)	3,464	(12,998)
Gross profit	**4,511**	**671**	**(569)**	**4,613**
Operating income and (expenses)				
Research and development expenses	(297)	(3,244)	569	(2,972)
Selling, general and administrative expenses	(3,299)	(1,057)	-	(4,356)
Amortisation of intangible assets	(665)	(95)	-	(760)
Other operating income	440	12	-	452
Other operating expenses	(459)	-	-	(459)
Total operating expenses	**(4,280)**	**(4,384)**	**569**	**(8,095)**
Operating income (loss)	**231**	**(3,713)**	**-**	**(3,482)**
EBITDA adjusted	**2,261**	**(3,569)**	**-**	**(1,308)**

5. ACQUISITIONS

Effective 01 April 2014, Evotec acquired 100% of the shares in Bionamics GmbH, Hamburg.
The purchase price of T€ 599 in cash included a potential earn-out as contingent consideration in the amount of T€ 115. The earn-out was calculated based on estimated future revenues in the 48 months following the date of acquisition with a discount of 1.56%. The estimated maximum potential earn-out payment amounts to T€ 364.

Evotec acquired 100% of the shares in Euprotec Ltd, Manchester, UK, effective 27 May 2014.
The purchase price of T€ 3,698 in cash included a potential earn-out as contingent consideration. The earn-out in the amount of T€ 677 as contingent consideration was calculated based on estimated future revenues as well as estimated achievement of a defined future milestones in the 31 months following the date of acquisition with a discount rate of 2.03%. The discount rate was based on usual market interest rate on debt. The maximum potential earn-out payment amounted to T€ 1,544 as of the date of the acquisition.
According to IFRS 3 and due to the preliminary assessment of the initial accounting for the acquisition of Euprotec, the initial accounting is provisional with regard to purchase price allocation and the fair values used to identify the purchase price and the assets and liabilities of the combination. It may therefore be subject to changes.

6. TRADE ACCOUNTS RECEIVABLES

The decrease in trade accounts receivables from 31 December 2014 to 31 March 2015 is primarily due to milestones that were recorded in 2014 and paid in the first quarter of 2015.

7. OTHER CURRENT FINANCIAL ASSETS

The other current financial assets as of 31 March 2015 increased compared to 31 December 2014 primarily due to received credit notes in the amount of T€ 678 relating to royalty income.

8. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets as of 31 March 2015 primarily consisted of prepaid expenses in the amount of T€ 5,605 (31 December 2014: T€ 4,293) which are recognised over different time periods. The increase in prepaid expenses as of 31 March 2015 compared to 31 December 2014 mainly relates to prepayments for the rest of the year.

9. TRADE ACCOUNTS PAYABLES

The decrease in trade accounts payables as of 31 March 2015 in comparison with 31 December 2014 is mainly due to payments related to the Sanofi transaction and to the alliance with Haplogen Furthermore, this decrease results from a significant volume of compound purchases that had been invoiced at 31 December 2014.

10. CURRENT PROVISIONS

The increase in provisions as of 31 March 2015 in comparison with 31 December 2014 primarily relates to the increase in the current portion of the earn-out relating to the acquisition of Euprotec in the amount of T€ 186 and further to increased provisions for personnel expenses due to a portion of the bonus 2014 being only paid in April 2015 (€ 0.4 m).

11. NON-CURRENT LOAN LIABILITIES

The increase in non-current loan liabilities relates to the issuance of a new loan portion out of an existing loan agreement. The loan is unsecured and has a maturity until 31 March 2021. Repayment of the loan will start on 30 June 2016 in equal instalments until the maturity date. The loan carries an interest at a rate of 1.25%.

12. NON-CURRENT PROVISIONS

The increase in non-current provisions relates mainly to the fair value adjustments of earn-out provisions in the context of the acquisitions of DeveloGen (T€ (95)), Bionamics (T€ 69) and Euprotec (T€ 927).

13. FAIR VALUES OF FINANCIAL ASSETS AND LIABILITIES

The fair values of financial assets and liabilities, together with the carrying amounts shown in the balance sheet as of 31 March 2015, are as follows:

In T€	31 March 2015 Carrying amount	Fair value
Cash and cash equivalents	49,284	49,284
Available-for-sale financial assets		
Investments	46,490	46,490
Long-term investments	-	-
Total available-for-sale financial assets	46,490	46,490
Financial assets measured at fair value		
Derivative financial instruments	-	-
Other non-current financial assets	78	78
Total financial assets measured at fair value	78	78
Loans and receivables		
Trade accounts receivables	13,804	13,804
Other current financial assets	1,908	1,908
Total loans and receivables	15,712	15,712
Financial liabilities measured at amortised cost		
Current loan liabilities	(13,512)	(13,512)
Non-current loan liabilities	(8,719)	(8,676)
Current portion of finance lease obligations	-	-
Long-term finance lease obligations	-	-
Trade accounts payables	(6,822)	(6,822)
Other current financial liabilities	(110)	(110)
Total financial liabilities measured at amortised cost	(29,163)	(29,120)
Financial liabilities measured at fair value		
Derivative financial instruments	(888)	(888)
Contingent consideration	(17,118)	(17,118)
Total financial liabilities measured at fair value	(18,006)	(18,006)
	64,395	64,438
Unrecognised (gain)/loss		(43)

The following table allocates financial assets and financial liabilities as of 31 March 2015 to the three levels of the fair value hierarchy as defined in IFRS 13:

	31 March 2015 Level 1	Level 2	Level 3	Total
	T€	T€	T€	T€
Available-for-sale financial assets	46,490	-	-	46,490
Financial assets measured at fair value	-	78	-	78
Financial liabilities measured at fair value	-	(888)	(17,118)	(18,006)

The following table shows the movement of the fair values at level 3 from the beginning balances to 31 March 2015:

In T€	January to March 2015 Investments	Contingent consideration
Balance at 01 January 2015	-	15,864
Exchange rate differences	-	48
Consumption	-	-
Included in other operating expense		
Changes in fair value, unrealised	-	996
Included in other operating income		
Changes in fair value, unrealised	-	(95)
Included in interest expense		
Interest change in net present value, unrealised	-	305
Balance at 31 March 2015	-	17,118

The levels of the fair value hierarchy and its application to Evotec's financial assets and financial liabilities are described below:

Level 1: Quoted prices in active markets for identical assets or liabilities;
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
Level 3: Inputs for the asset or liability that are not based on observable market data.

14. TRANSACTIONS WITH RELATED PARTIES

Except for the transactions described in Evotec's Annual Report 2014 on page 114, no other material transactions with related parties were entered into in the first three months of 2015.

15. SUBSEQUENT EVENTS

Closed on 31 March 2015 and effective 01 April 2015, Evotec entered into a major multi-component strategic alliance with Sanofi over the next five years. This multi-faceted collaboration encompasses a long-term discovery service collaboration with Sanofi, a planned major pipeline-building initiative with a focus on oncology and the acquisition of Sanofi's research site in Toulouse.